Product Information
ZOLMITRIPTAN 5 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $1.3533 per EA under NDC 16571080413. Its NADAC has been published 250 times since Dec 22, 2021.
FDA first approved this application on May 11, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571080413
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ZOLMITRIPTANApproval Type
Generic (ANDA)
FDA Application
ANDA207021FDA Approved
5/11/2016
TE Code
AB
On Market Since
5/11/2016
Pharmacological Classes
Price Statistics
The NADAC for ZOLMITRIPTAN 5 MG TABLET has been published 250 times since Dec 22, 2021, and over the history we have for it it has declined 8.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.3533 per EA |
|---|---|
| All-time high | $2.1466 (Feb 16, 2022) |
| All-time low | $1.1137 (May 22, 2024) |
| 52-week high | $1.5666 |
| 52-week low | $1.2261 |
| Median price | $1.4650 |
| Average price | $1.4866 |
| Largest weekly change | +45.4% (Jan 19, 2022) |
| Weeks tracked | 250 |
| Tracking since | Dec 22, 2021 |
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Zolmitriptan market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin-1b and Serotonin-1d Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZOLMITRIPTAN 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ZOLMITRIPTAN 5 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $1.3533 per EA (NDC 16571080413), effective Sep 30, 2026.
How has the price of ZOLMITRIPTAN 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for ZOLMITRIPTAN 5 MG TABLET has declined 8.3%. It has been tracked across 250 weekly CMS publications since Dec 22, 2021.
What are the highest and lowest recorded NADAC prices for ZOLMITRIPTAN 5 MG TABLET?
Since Dec 22, 2021, the NADAC for ZOLMITRIPTAN 5 MG TABLET has ranged from a low of $1.1137 (May 22, 2024) to a high of $2.1466 (Feb 16, 2022), with a median of $1.4650 per EA.
Are there cheaper alternatives to ZOLMITRIPTAN 5 MG TABLET?
9 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ZOLMITRIPTAN 5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures ZOLMITRIPTAN 5 MG TABLET?
ZOLMITRIPTAN 5 MG TABLET (NDC 16571080413) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.